Mar. 23 -- FRIDAY, June 22 (HealthDay News) -- A drug derived from the sea squirt showed anti-tumor activity in more than half of 51 patients with a type of cancer called advanced pretreated myxoid ...

From May 2011 to June 2020, 101 patients with HG-MLPS were randomly assigned, 45 to the HT arm and 56 to the S arm. The median follow-up was 66 months (IQR, 37-89). Median size was 107 mm (IQR, 84-143 ...

Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. The Food and Drug Administration (FDA) has ...

Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.

A rare form of cancer is gaining awareness and important research funding thanks to a nationwide and global event that started here in the Capital Region. the 11th annual Sarcoma Strong 5K brought ...